

\$162

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER OF PATENTS, WASHINGTON, DC 20231, ON THE DATE INDICATED BELOW.

BY: Patent Application DATE: Apr 22 2002

BOX PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re: Patent Application of : Group Art Unit: 1652
Emil C. Gotschlich :
:
:
Appln. No.: 10/007,267 : Examiner: To Be Assigned
:
Filed: December 3, 2001 :
:
For: GLYCOSYLTRANSFERASES FOR : Attorney Docket
BIOSYNTHESIS OF : No. 040853-01-5029-02
OLIGOSACCHARIDES AND GENES :
ENCODING THEM :

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

APR 26 2002

AMENDMENT TRANSMITTAL LETTER

TECH CENTER 1600/2900

Transmitted herewith is an Amendment in the above-identified application.

- ☐ Substitute Specification.
☒ Small Entity status:
☒ has previously been claimed/established.
☐ is hereby claimed under 37 C.F.R. §1.27, as ☐ an Independent Inventor, or ☐ a Small Business Concern, or ☐ a Non-Profit Organization.

The additional claim fees have been calculated as follows:

					SMALL ENTITY		LARGE ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE	RATE	ADDIT. FEE
TOTAL	16	(-)	20		x\$9		x\$18	
INDEP.	6	(-)	3	3	x\$42	126.00	x\$84	
<input type="checkbox"/> 1st PRESENTATION OF MULTIPLE DEPENDENT CLAIMS					x\$140		+\$280	
					TOTAL	\$126.00	TOTAL	

The additional claim fees are being paid by:

- ☐ A check in the amount of \$_____.
- ☒ Authorization to charge and/or credit **Deposit Account No. 50-0310 (Billing No. 040853-01-5029-02)** as noted below. A duplicate copy of this sheet is enclosed.
- ☒ Any overpayments or deficiencies in the above-calculated fee.
- ☒ Additional claim fee in the amount of **\$126.00** as calculated above.
- ☒ Any additional fees required under 37 C.F.R. § 1.16 and/or § 1.17.
- ☐ In the event that a Petition for Extension of Time is required, but not submitted, please charge any extension fee under 37 C.F.R. § 1.136(a) to our Deposit Account.

CORRESPONDENCE ADDRESS

April 12, 2002
(Date)

By:

Kathryn Doyle
KATHRYN DOYLE, Ph.D, J.D.
Registration No. 36,317
MORGAN, LEWIS & BOCKIUS, LLP
1701 Market Street
Philadelphia, PA 19103-2921
Telephone: (215) 963-5000
Direct Dial: (215) 963-4723
Facsimile: (215) 963-5299
E-Mail: kdoyle@morganlewis.com
Attorney for Applicants


KD/kck
Enclosures

See

I HEREBY CERTIFY THAT THE CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER OF PATENTS, WASHINGTON, DC 20231, ON THE DATE INDICATED BELOW.

BY: Patricia C. Morrison

DATE: 4/12/02 April 12, 2002



BOX PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re: Patent Application of : Group Art Unit: 1652
Emil C. Gotschlich :
:
:
Appln. No.: 10/007,267 : Examiner: To Be Assigned
:
Filed: December 3, 2001 :
: Attorney Docket
For: GLYCOSYLTRANSFERASES FOR : No. 040853-01-5029-02
BIOSYNTHESIS OF :
OLIGOSACCHARIDES AND GENES
ENCODING THEM

APR 26 2002

TECH CENTER 1600/29

COPY OF PAPERS
ORIGINALLY FILED

SECOND PRELIMINARY AMENDMENT

Preliminary to the examination of the above-identified application, please amend the application as follows:

In the claims:

Please cancel claims 27, 32, and 33, without prejudice. Please add new claims 34-49, as follows:

34. (New) A glycosyltransferase comprising the amino acid sequence SEQ ID NO:2, or a functionally active fragment thereof.

35. (New) A glycosyltransferase comprising the amino acid sequence SEQ ID NO:3, or a functionally active fragment thereof.

36. (New) A glycosyltransferase comprising the amino acid sequence SEQ ID NO:4, or a functionally active fragment thereof.

37. (New) A glycosyltransferase comprising the amino acid sequence SEQ ID NO:5, or a functionally active fragment thereof.

38. (New) A glycosyltransferase comprising the amino acid sequence SEQ ID NO:6, or a functionally active fragment thereof.

39. (New) A composition comprising a glycosyltransferase conjugated to a solid phase support, wherein the glycosyltransferase is selected from the group consisting of:

a) a glycosyltransferase comprising the amino acid sequence SEQ ID NO:2, or a functionally active fragment thereof;